Dyslipidaemia: Focus shifts from LDL-C to HDL-C

Abstract

In this current analysis of the antidyslipidaemics market, a shift in focus from low-density lipoprotein cholesterol (LDL-C)-targeted therapies to drugs that elevate high-density lipoprotein cholesterol (HDL-C) is described. Key reasons for this evolution are several-fold, but mainly focus on significant generic erosion of LDL-C-targeted therapies, particularly the statins, and loss of revenues therein. Additionally, with LDL-C-lowering efficacy unlikely to improve without sacrificing patient safety, elevating HDL-C has emerged as a therapeutic option in the long-running battle against coronary heart disease.